Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 2
1989 5
1990 2
1991 4
1992 3
1993 4
1994 5
1995 3
1996 4
1997 7
1998 3
1999 2
2000 11
2001 3
2002 14
2003 5
2004 7
2005 10
2006 7
2007 6
2008 13
2009 6
2010 8
2011 14
2012 11
2013 11
2014 11
2015 18
2016 20
2017 17
2018 20
2019 19
2020 23
2021 22
2022 19
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Results by year

Filters applied: . Clear all
Page 1
Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Liu AY, et al. Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17. Lancet Haematol. 2016. PMID: 27063975 Review.
First-line treatments for idiopathic multicentric Castleman's disease included corticosteroids (47/128 [37%]), cytotoxic chemotherapy (47/128 [37%]), and anti-interleukin 6 therapy (11/128 [9%]). 49 (42%) of 116 patients failed first-line therapy, 2-year survival was 88% (95% CI …
First-line treatments for idiopathic multicentric Castleman's disease included corticosteroids (47/128 [37%]), cytotoxic chemotherapy (47/12 …
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. van Rhee F, et al. Blood Adv. 2020 Dec 8;4(23):6039-6050. doi: 10.1182/bloodadvances.2020003334. Blood Adv. 2020. PMID: 33284946 Free PMC article.
Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. ...The first-ever diagnostic and treatment guidelines were recently developed for iMCD by an international expert consortium c …
Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological a …
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, Mango N, Lavery C, Austin B, Alapat D, Lechowicz MJ, Bagg A, Li H, Casper C, van Rhee F, Fajgenbaum DC. Pierson SK, et al. Blood Adv. 2023 Nov 14;7(21):6652-6664. doi: 10.1182/bloodadvances.2023010745. Blood Adv. 2023. PMID: 37656441 Free PMC article.
Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder with an unknown etiology. ...Anti-IL6-directed therapy with siltuximab or tocilizumab demonstrated better response and more durability than was observed with rituximab w/wo cortic …
Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder with an unknown etiology. ...Anti-IL6-directed …
Imaging and clinical features of Castleman Disease.
Zhao S, Wan Y, Huang Z, Song B, Yu J. Zhao S, et al. Cancer Imaging. 2019 Jul 25;19(1):53. doi: 10.1186/s40644-019-0238-0. Cancer Imaging. 2019. PMID: 31345268 Free PMC article.
BACKGROUND: Castleman disease (CD) is a group of uncommon lymphoproliferative disorders that is easily confused with lymphoma or other solid tumors. ...RESULTS: The CD subtypes included 61 hyaline vascular variant cases (82.4%) and 13 plasma cell variant cases (17.6 …
BACKGROUND: Castleman disease (CD) is a group of uncommon lymphoproliferative disorders that is easily confused with lymphoma …
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC. Fajgenbaum DC. Blood. 2018 Nov 29;132(22):2323-2330. doi: 10.1182/blood-2018-05-848671. Blood. 2018. PMID: 30487129 Free PMC article. Review.
Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. ...Several clinicopathological analyses provided the evidence base for the first-ever diagnostic criteria and revealed distinct clini …
Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopath …
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC. Fajgenbaum DC. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):318-325. doi: 10.1182/asheducation-2018.1.318. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504327 Free PMC article. Review.
Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. ...Several clinicopathological analyses provided the evidence base for the first-ever diagnostic criteria and revealed distinct clini …
Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopath …
Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Katano H. Katano H. Adv Exp Med Biol. 2018;1045:357-376. doi: 10.1007/978-981-10-7230-7_16. Adv Exp Med Biol. 2018. PMID: 29896675 Review.
In addition to Kaposi's sarcoma, KSHV has been detected in primary effusion lymphoma, KSHV-associated lymphoma, and some cases of multicentric Castleman disease (MCD). Recently, KSHV inflammatory cytokine syndrome (KICS) was also defined as a KSHV-associated disease …
In addition to Kaposi's sarcoma, KSHV has been detected in primary effusion lymphoma, KSHV-associated lymphoma, and some cases of multicentr …
Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases.
Sun DP, Chen WM, Wang L, Wang Z, Liang JH, Zhu HY, Fan L, Wu YJ, Xu W, Li JY. Sun DP, et al. J Cancer Res Clin Oncol. 2021 Jul;147(7):2107-2115. doi: 10.1007/s00432-020-03494-2. Epub 2021 Feb 5. J Cancer Res Clin Oncol. 2021. PMID: 33544201 Free PMC article.
PURPOSE: To explore the clinical features and immunological mechanisms of Castleman disease (CD) complicated with autoimmune diseases (AID). ...Deregulated cellular and innate immune responses as indicated by decreased CD3(+) T cells and increased natural killer cel …
PURPOSE: To explore the clinical features and immunological mechanisms of Castleman disease (CD) complicated with autoimmune d …
HIV-associated multicentric Castleman disease.
Oksenhendler E. Oksenhendler E. Curr Opin HIV AIDS. 2009 Jan;4(1):16-21. doi: 10.1097/coh.0b013e328319bca9. Curr Opin HIV AIDS. 2009. PMID: 19343828 Review.
SUMMARY: Etoposide is the most effective first-line therapy for active multicentric Castleman disease. Rituximab can be used after an initial control of the attack and provides a 1-yearremission rate above 70%. Exacerbation of Kaposi sarcoma lesions, observed …
SUMMARY: Etoposide is the most effective first-line therapy for active multicentric Castleman disease. Rituximab can be used a …
Clinical and histopathology characteristics of Castleman disease: a multicenter study of 51 Brazilian patients.
Leite JM, Barrese TZ, Sementilli L, de Freitas LLL, do Espirito Santo KS, Delamain MT, Baiocchi OCCG, Brasil SAB, Chiattone CS. Leite JM, et al. Ann Hematol. 2023 May;102(5):1121-1129. doi: 10.1007/s00277-023-05116-6. Epub 2023 Feb 10. Ann Hematol. 2023. PMID: 36763110
Of the patients with UCD, 94.7% underwent excisional biopsy, against only 41.2% of patients with MCD (p = 0.01). The mean follow-up was 61 months. We observed similarities in the clinical profile between patients in our study and patients described in the literature, such …
Of the patients with UCD, 94.7% underwent excisional biopsy, against only 41.2% of patients with MCD (p = 0.01). The mean follow-up was 61 m …
334 results